Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

A Molecular Hinge Allows Transport Proteins to Move Neurotransmitters Across Brain Cell Membranes

By BiotechDaily International staff writers
Posted on 13 May 2013
Print article
Image: Senior author Dr. Shimon Schuldiner (Photo courtesy of the Hebrew University of Jerusalem).
Image: Senior author Dr. Shimon Schuldiner (Photo courtesy of the Hebrew University of Jerusalem).
An international team of molecular biologists has developed a model that shows how components of a protein transport complex act as a molecular hinge to move neurotransmitters across brain cell membranes.

Investigators at the Hebrew University of Jerusalem (Israel) and the Max Planck Institute of Biophysics (Frankfurt am Main, Germany) focused on vesicular monoamine transporter 2 (VMAT2), a member of the largest superfamily of transporters, which is known to convey a variety of neurotransmitters such as adrenaline, dopamine, and serotonin as well as MPP, a neurotoxin linked to Parkinson’s disease.

In the April 9, 2013, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) they described the importance of two anchor points positioned between two six-transmembrane-helix bundles. These two domains provide hinge points about which the two halves of the protein flex and straighten to open and close the translocation pathway, a process that enables alternating exposure of the substrate-binding site. Polar residues that create a hydrogen bond cluster form one of the anchor points of VMAT2, while the other results from hydrophobic interactions.

The investigators, led by Dr. Shimon Schuldiner, professor of biochemistry at the Hebrew University of Jerusalem, said that, "They hope that this knowledge may, in the future, help in designing drugs for treating pathologies involving transporters similar to VMAT, including infectious and neurological diseases."

Related Links:
Hebrew University of Jerusalem
Max Planck Institute of Biophysics



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.